ArticleBritish journal of cancer2016
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- Pleomorphism in Soft Tissue Sarcomas: Molecular Characteristics and Clinical Features.Medical sciences (Basel, Switzerland) · 2026Review
- Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.Journal for immunotherapy of cancer · 2024Article
- Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.Theranostics · 2024Review
- From bench to bedside:EJNMMI research · 2023Article
- CD248 promotes migration and metastasis of osteosarcoma through ITGB1-mediated FAK-paxillin pathway activation.BMC cancer · 2023Article
- Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma.Molecular cancer therapeutics · 2023Article
- Retroperitoneal undifferentiated pleomorphic sarcoma with total nephrectomy: a case report and literature review.Frontiers in surgery · 2023Article
- Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.Frontiers in genetics · 2023Review
- Interference in melanoma CD248 function reduces vascular mimicry and metastasis.Journal of biomedical science · 2022Article
- Tumor endothelial marker 1 is upregulated in heart after cardiac injury and participates in cardiac remodeling.Scientific reports · 2022Article
- Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review.Biomedicines · 2021Review
- Antibody Conjugates for Sarcoma Therapy: How Far along Are We?Biomedicines · 2021Review
- Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review.Cancers · 2021Review
- Article
- Preclinical Evaluation and Dosimetry of [Molecular imaging and biology · 2020Article
- CD248: A therapeutic target in cancer and fibrotic diseases.Oncotarget · 2019Review
- MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.Cancer biomarkers : section A of Disease markers · 2018Article
- Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.Oncotarget · 2017Article
- Heparin regulates B6FS cell motility through a FAK/actin cytoskeleton axis.Oncology reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms of other lineages, and establishing an accurate histopathological diagnosis is crucial for correct management, and therapeutic stratification. The endosialin cell surface glycoprotein is predominantly expressed by stromal fibroblasts and pericytes in epithelial neoplasms; however, tumour cell expression has been reported in small series of sarcomas.
methodsWe assessed endosialin expression by immunohistochemistry in a large set of 514 human soft tissue sarcomas.
resultsTumour cell endosialin expression was seen in 89% of undifferentiated pleomorphic sarcomas (104/117), 77% adult fibrosarcomas/spindle cell sarcomas (20/26), 62% synovial sarcomas (37/60), 51% leiomyosarcomas (94/185) and 31% rhabdomyosarcomas (39/126).
conclusionsEndosialin immunohistochemistry has potential to distinguish undifferentiated and poorly differentiated sarcomas from other poorly differentiated, non-mesenchymal neoplasms. A Phase II trial randomising patients with advanced sarcomas to receive chemotherapy with/without an endosialin therapeutic antibody has recently completed enrolment. Endosialin expression could be used to select patients for such clinical trials. Based on our results, patients with undifferentiated pleomorphic sarcoma may be particularly suitable for such a therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.